Mycopathologia, Journal Year: 2023, Volume and Issue: 188(6), P. 1041 - 1053
Published: Oct. 20, 2023
Language: Английский
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(7), P. e428 - e438
Published: Jan. 21, 2024
Language: Английский
Citations
458
Open Forum Infectious Diseases, Journal Year: 2022, Volume and Issue: 9(12)
Published: Dec. 1, 2022
Fungal disease is frequent in India, but its incidence and prevalence are unclear. This review aims at defining the frequency or burden of various fungal infections India.
Language: Английский
Citations
43
Therapeutic Advances in Infectious Disease, Journal Year: 2024, Volume and Issue: 11
Published: Jan. 1, 2024
It is of utmost importance to monitor any change in the epidemiology fungal diseases that may arise from a number at-risk population or availability local data.
Language: Английский
Citations
11
Mycopathologia, Journal Year: 2025, Volume and Issue: 190(1)
Published: Jan. 7, 2025
Language: Английский
Citations
1
Mycoses, Journal Year: 2025, Volume and Issue: 68(2)
Published: Feb. 1, 2025
ABSTRACT Background Post‐tuberculosis lung disease (PTLD) is a precursor to Aspergillus ‐related diseases. While Chronic Pulmonary Aspergillosis (CPA) has been extensively studied in the background of tuberculosis, Allergic Bronchopulmonary (ABPA) reported sporadically with limited information on its prevalence, clinical‐radiological features, and treatment outcomes. Objective This study, conducted high TB burden setting, aimed address this knowledge gap by systematically evaluating ABPA PTLD patients. Methods retrospective cohort study screened patients presenting respiratory or constitutional symptoms persisting for more than 3 months. The objective was report clinical‐radiological‐laboratory data, outcomes ABPA‐PTLD compared CPA (CPA‐PTLD) (PTLD only). Results Out total 1012 patients, seen 2.27%, 20.75% sensitization 0.7%. primarily presented breathlessness (91.3%) cough (82.6%) while haemoptysis (43.5%), weight loss (13%), anorexia (21.7%) were also observed, albeit less commonly CPA‐PTLD. Bronchiectasis (100%) nodules (87%) frequent whereas consolidation (21.7%), cavities (30.4%), pleural thickening (8.7%), ‘fungal ball’ (9.1%) seen, although Most received azoles (78%) as first‐line therapy, symptomatic improvement (partial/complete) observed ~78%. Conclusion may occur specific clinical (e.g., haemoptysis) radiological cavity fungal ball) features uncommon other types ABPA, but resembling conditions. Future studies should focus identifying differences natural course appropriate paradigms occurring asthma cystic fibrosis
Language: Английский
Citations
1
Journal of Investigative Medicine High Impact Case Reports, Journal Year: 2025, Volume and Issue: 13
Published: March 1, 2025
Co-infection with Mycobacterium tuberculosis and Aspergillus in an immunocompetent host is rare but can occur. In this case, we present a patient central nervous system (TB) biopsy-proven spinal co-infections TB Aspergillosis. We highlight the complexities of treating TB-Aspergillosis co-infection given drug-drug interactions between standard therapy for both conditions. Using susceptibilities carefully monitoring drug levels antifungal agents, were able to optimally treat co-infection. This was ultimately discharged on isoniazid 1200 mg (15 mg/kg) daily, levofloxacin 750 rifabutin 450 posaconazole 300 twice daily tentative plan at least 1 year close outpatient follow-up. case serve as guide other providers who need cases Aspergillosis by learning from our experience paying attention potential pitfalls.
Language: Английский
Citations
1
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Citations
5
Mycology: An International Journal on Fungal Biology, Journal Year: 2023, Volume and Issue: 14(2), P. 142 - 154
Published: April 3, 2023
The burden of fungal infections has been on the rise globally and remains a significant public health concern in Kenya. We estimated incidence prevalence using all mycology publications Kenya up to January 2023, from neighbouring countries where data lacked. used deterministic modelling populations at risk calculate disease burden. total serious is affect 6,328,294 persons which translates 11.57% Kenyan population. Those suffering chronic such as pulmonary aspergillosis are be 100,570 people (0.2% population) probably nearly 200,000 with asthma, treatable oral antifungal therapy. Serious acute secondary HIV (cryptococcal meningitis, disseminated histoplasmosis, pneumocystis pneumonia, mucosal candidiasis) 196,543 adults children (0.4% population), while cancer-related invasive infection cases exceed 2,299 those intensive care about 1,230 incident cases, including
Language: Английский
Citations
12
Open Forum Infectious Diseases, Journal Year: 2024, Volume and Issue: 11(4)
Published: Feb. 15, 2024
Abstract Background Chronic pulmonary aspergillosis (CPA) is an underrecognized but common complication of tuberculosis. In Nigeria, a tuberculosis-endemic country, there currently no provision to monitor the development CPA in patients treated for This study determined prevalence and incidence Lagos, Nigeria. Methods A prospective longitudinal with previously managed tuberculosis was conducted between June 2021 May 2022. The cohorts were assessed at 3-month intervals, following collected: sociodemographic data, chest radiographic findings, sputum samples fungal culture, venous blood Aspergillus immunoglobulin G estimation. cases using case definition resource-constrained countries. Descriptive inferential statistics used, significance set probability 5% (P < .05). Results Of 141 recruited, 79 (56.0%) retreatment 62 (44.0%) posttreatment group. median age (interquartile range) 40 (30–52) years, male-to-female ratio 1.1:1. Ninety-seven (69%) had GeneXpert test done, whom 63 (64.9%) negative. Cough most symptom, 15 (11%) having hemoptysis. rate increased steadily as progressed: 44 (31.2%) commencement, 45 (34.9%) 3 months, 49 (42.6%) 6 51 (54.3%) 9 months. Thus, overall 49.7%, 6.1%. Conclusions Nigeria its true burden may still be underestimated. Increased awareness posttuberculosis lung disease advocated. Evaluation should incorporated patients’ work-up
Language: Английский
Citations
4
Mycoses, Journal Year: 2024, Volume and Issue: 67(5)
Published: May 1, 2024
Abstract Background Chronic pulmonary aspergillosis (CPA) is known to complicate patients with post‐tubercular lung disease. However, some evidence suggests that CPA might co‐exist in newly‐diagnosed tuberculosis (P.TB) at diagnosis and also develop during therapy. The objective of this study was confirm the presence newly diagnosed P.TB baseline end‐of‐TB‐therapy. Materials Methods This prospective longitudinal included patients, followed up third month end‐of‐TB‐therapy symptom assessment, anti‐ Aspergillus IgG antibody imaging chest for diagnosing CPA. Results We recruited 255 out which 158 (62%) completed their follow‐up. Anti‐ positive 11.1% 27.8% Overall, proven 7% 14.5% Around 6% had aspergilloma CT Conclusions can be present anti‐tubercular treatment. Patients persistent symptoms or developing new treatment should evaluated Whether concomitant CPA, while receiving antitubercular therapy, need additional antifungal needs future studies.
Language: Английский
Citations
4